Figure 10.
Recombinant IL-22 decreases CXCR3 expression by CD4+ T cells and levels of CXCL9 in the lung. (A) Representative density plots of CXCR3 expression by CD4+ T cells isolated from the lung of WT C57BL6, B6.AhRd/d, and B6.TCRδ−/− mice treated with a combination of recombinant IL-22 and B. subtilis or vehicle and B. subtilis for four consecutive weeks. CD4+ T cells were selected from a bivariate dot plot of CD3+CD4+ cells from the lymphocyte gate. The percentage of CD3+CD4+ T cells expressing CXCR3 is shown in the top right quadrant of the density plot. Data represent at least five individual mice per experiment from two separate experiments. (B) Number of CXCR3-expressing CD4+ T cells in the lung of WT C57BL/6 (wt), B6.AhRd/d (AhR), and B6.TCRδ−/− (δ−/−) mice treated with a combination of recombinant IL-22 and B. subtilis or vehicle and B. subtilis for four consecutive weeks. Data were compiled from at least five individual mice per experiment from two separate experiments. (C) Levels of CXCL9, 10, and 11 in the lung of WT C57BL/6 (•), B6.Vγ6+/+ (■), and B6.TCRδ−/− (▴) mice treated with B. subtilis for four consecutive weeks compared with PBS control. The asterisks denote a statistically significant (P < 0.05) difference in lung chemokine concentration at each time point between B6.TCRδ−/− and B6.Vγ6+/+ mice. Data were compiled from at least five individual mice at each time point from two separate experiments (mean ± SD). (D) Levels of CXCL9 in the lung of WT C57BL/6, TCR-δ−/−, and AhRd/d mice treated with a combination of recombinant IL-22 and B. subtilis, B. subtilis, or PBS for four consecutive weeks. The mean is shown as a solid line. Data were compiled from five individual mice from two separate experiments. (E) Levels of CXCL9 in the lung of B6.Vγ6+/+ mice treated with a combination of the AhR inhibitor, CH-223191, and B. subtilis, B. subtilis, or PBS for four consecutive weeks. The mean is shown as a solid line. Data were compiled from five individual mice from two separate experiments.